---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-020183"
form_type: "8-K"
ticker: "JANX"
cik: "0001817713"
company_name: "Janux Therapeutics, Inc."
filed_at: "2024-02-26T23:59:59+00:00"
generated_at: "2026-06-05T15:37:20.042392+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Janux announces encouraging safety/efficacy data for JANX007 in mCRPC and JANX008 in solid tumors

## Summary
- JANX007: 5/6 (83%) PSA50 declines at step dose ≥0.2 mg; 10/18 (56%) at ≥0.1 mg; no Grade 3+ CRS.
- JANX008: NSCLC subject achieved confirmed PR with 100% target lung lesion reduction and elimination of liver metastasis; no CRS or TRAEs.
- JANX008: No Grade 2+ CRS, no treatment-related SAEs or DLTs across 11 heavily pretreated patients across 4 tumor types.
- Janux hosting virtual investor event today at 4:30 PM ET to discuss data.

## SEC filing metadata
- accession: 0000950170-24-020183
- form_type: 8-K
- ticker: JANX
- cik: 0001817713
- company_name: Janux Therapeutics, Inc.
- filed_at: 2024-02-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817713/000095017024020183/0000950170-24-020183-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817713/000095017024020183/janx-20240226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-020183
- JSON: https://secwatch.observer/filing/0000950170-24-020183.json
- Plain text: https://secwatch.observer/filing/0000950170-24-020183.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.